Aptevo reports 87% clinical benefit in frontline AML trial; $60M credit line extends runway
Mipletamig achieved an 87% clinical benefit rate and 81% CR/CRi in 31 frontline AML patients, with 65% complete remission and no cytokine release syndrome. Aptevo raised a $60 million equity credit line to extend capital through 2029 and installed Jeff Lamothe as CEO with Marvin White as Executive Chair.
1. Clinical Data Highlights
Aptevo’s RAINIER Phase 1b/2 trial in frontline acute myeloid leukemia continues to demonstrate strong efficacy in 31 evaluable patients, with an 87% clinical benefit rate, an 81% combined CR/CRi rate and a 65% complete remission rate. Safety profile remains differentiated, with no cytokine release syndrome observed and 52% of remissions reaching MRD-negative status.
2. Leadership Transition
Executive leadership changes completed in Q1 2026, as Jeff Lamothe assumed the role of Chief Executive Officer and Marvin White transitioned to Executive Chair. The appointments maintain strategic continuity while aligning governance with anticipated clinical milestones and long-term value creation.
3. Financial Flexibility and Outlook
As of March 31, 2026, Aptevo held $14.5 million in cash and cash equivalents, supported by a net $0.9 million draw under existing capital agreements. In addition, a new $60 million standby equity line provides extended financial runway through 2029, bolstering resources for upcoming dose selection and trial completion.